{"title":"https://doi.org/10.1016/S1473-3099(24)00615-7","authors":"","doi":"10.1016/s1473-3099(24)00721-7","DOIUrl":null,"url":null,"abstract":"<em>Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.</em> Lancet Infect Dis <em>2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7</em>—In this Correspondence, the figure labels have been corrected with ARCT-154 labelled red and BNT162b2 as blue. These corrections have been made to the online version as of Oct 18, 2024.","PeriodicalId":49923,"journal":{"name":"Lancet Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":36.4000,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7\",\"authors\":\"\",\"doi\":\"10.1016/s1473-3099(24)00721-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.</em> Lancet Infect Dis <em>2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7</em>—In this Correspondence, the figure labels have been corrected with ARCT-154 labelled red and BNT162b2 as blue. These corrections have been made to the online version as of Oct 18, 2024.\",\"PeriodicalId\":49923,\"journal\":{\"name\":\"Lancet Infectious Diseases\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":36.4000,\"publicationDate\":\"2024-10-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s1473-3099(24)00721-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s1473-3099(24)00721-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
摘要
Oda Y, Kumagai Y, Kanai M, et al:ARCT-154与BNT162b2疫苗。Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7-In this Correspondence, the figure labels have been corrected with ARCT-154 labelled red and BNT162b2 as blue.这些更正已在 2024 年 10 月 18 日的在线版本中做出。
Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7
Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7—In this Correspondence, the figure labels have been corrected with ARCT-154 labelled red and BNT162b2 as blue. These corrections have been made to the online version as of Oct 18, 2024.
期刊介绍:
The Lancet Infectious Diseases was launched in August, 2001, and is a lively monthly journal of original research, review, opinion, and news covering international issues relevant to clinical infectious diseases specialists worldwide.The infectious diseases journal aims to be a world-leading publication, featuring original research that advocates change or sheds light on clinical practices related to infectious diseases. The journal prioritizes articles with the potential to impact clinical practice or influence perspectives. Content covers a wide range of topics, including anti-infective therapy and immunization, bacterial, viral, fungal, and parasitic infections, emerging infectious diseases, HIV/AIDS, malaria, tuberculosis, mycobacterial infections, infection control, infectious diseases epidemiology, neglected tropical diseases, and travel medicine. Informative reviews on any subject linked to infectious diseases and human health are also welcomed.